Carvestad 6.25 Stella medicine for hypertension, angina (3 blisters x 10 tablets)

Dosage form Box of 3 blisters x 10 tablets
Specifications Carvedilol
Ingredient Heart failure, high blood pressure, angina

Ingredient

Composition information	Content
Carvedilol	6.25mg

Uses

indications

Carvestad 6.25 drugs are indicated in the following cases:

Hypertension.

Stable angina. α1-ADRENERGIC. The main physiological activity of Carvedilol is to inhibit the stimulation of β-adrenergic receptors on the heart muscle (receptor β1), bronchial smooth muscles and blood vessels (receptors β2) and less than those of α1 receptors on blood vessel muscles.

Carvedilol has no intrinsic sympathetic enhancement (Owner β1) and only has weak membrane stability.

The vasodilation impact reduces the total peripheral resistance through α1-adrenergic blockers and reduces the sympathetic tone of Carvedilol plays a major role in the hypotension effect of the drug.

pharmacokinetics

absorption:

Carvedilol absorbs well through the digestive tract but is metabolized through the liver for the first time, absolutely used about 25%. The peak concentration in plasma is achieved after 1-2 hours.

Distribution:

The drug is highly soluble in lipids. More than 98% of Carvedilol binds to plasma proteins, mainly with albumin. The binding of protein in plasma does not depend on the concentration in the therapeutic dose. Carvedilol is an oil -body compound, base with an integral distribution in a stable state of approximately 115 l, showing significant distribution drugs into foreign tissue.

Metabolism - excretion: strong metabolic drugs through the liver, mainly by Cytochrom P450, isenzyme CYP2D6 and CYP2C9 and metabolites are excreted mainly through bile. Selling time is about 6-10 hours. Carvedilol accumulated in animal milk.

Before taking Carvestad 6.25 Stella medicine for hypertension, angina (3 blisters x 10 tablets)

How to use

Take oral use.

Dosage

Carvedilol's dose must be considered for each person and should adjust the dose according to the blood pressure response and the tolerance of each patient.

Hypertension

The starting dose is 12.5 mg x 1 time/ day, increasing to 25 mg x 1 time/ day after 2 days.

Another way, the starting dose of 6.25 mg x 2 times/day, after 1-2 weeks increased to 12.5 mg x 2 times/day.

If necessary, the dose may increase, at least 2 weeks apart, up to 50 mg x1 times/ day, or divided into several doses.

Dosage 12.5 mg x 1 time/ day may be suitable for elderly patients.

Stable angina

The recommended starting dose is 12.5 mg 2 times/day for 2 days.

After that, the treatment continues at a dose of 25 mg x 2 times/day.

If necessary, the dose can be increased slowly with a distance of at least 2 weeks.

Maximum daily recommendations are 100 mg divided into 2 times (50 mg x 2 times/day).

The recommended starting dose is 12.5 mg 2 times/day for 2 days may be suitable for elderly patients. After that, the treatment continues at a dose of 25 mg x 2 times/day, this is the maximum daily recommendation.

SECRETING HEART

The starting dose of 3,125 mg x 2 times/ day, used with food to reduce the risk of hypotension.

If tolerant, the dose should be doubled after 2 weeks (6.25 mg x 2 times/ day) and then slowly increased, with a distance not less than 2 weeks, to the maximum dose of tolerance, this dose must not exceed 25 mg x 2 times/ day for patients with severe heart failure or weighing less than 85 kg, or 50 mg x 2 times/ day for patients with mild to medium heart failure over 85 kg.

Left ventricular dysfunction after myocardial infarction

The starting dose is 6.25 mg x 2 times/ day, after 3-10 days, the dose is increased to 12.5 mg x 2 times/ day if tolerated and then increased to the target dose of 25 mg x 2 times/ day.

Lower starting dose may be used for symptoms.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What to do when overdose? Respiratory problems, bronchospasm, vomiting, loss of autonomy and total seizures can occur.

Patients need to be placed in their lying position, monitoring and treating under special care conditions. Stomach lavage or pharmacological vomiting can be used immediately after swallowing.

What to do when you forget 1 dose? However, if the time to relax with the next dose is too short, skip the dose and continue the calendar of the drug. Do not use double dose to compensate for missed dose.

Side Effects

When using Carvestad 6.25, you may experience unwanted effects (ADR).

Common, ADR> 1/100

Systemic: headache, muscle aches, fatigue, shortness of breath.

Circulation: dizziness, posture hypotension. digestive: nausea.

Uncommon, 1/1000

Circulation: Slow heart rate.

digestive: diarrhea, abdominal pain.

Rare, 1/10000

Blood: platelets, leukopenia.

Perpetual: poor air conditioning, fainting.

Central Neurology: depression, sleep disorders, paresthesia. digestive: vomiting, constipation. skin: urticaria, itching, psoriasis.

Liver: Increase liver transaminase.

eyes: Reduce tears, irritation.

Respiratory: Stuffy nose.

Instructions on how to handle ADR

When experiencing side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

contraindicated

Carvestad 6.25 drug contraindicated in the following cases:

Bronchial asthma or diseases related to bronchospasm;

Atrial atrial clog II or III;

Pathological sinus syndrome or severe heart rate (unless using regular heart rate air conditioning);

Cardioma;

Sound congestive heart failure needs to use intravenous therapy of muscle -oriented drugs;

liver failure;

Hypersensitivity to Carvedilol or any of the drugs of the drug.

Be cautious when using

Carvestad 6.25 contains lactose. This drug should not be used for patients with rare genetic problems galactose intolerance, total lactase enzyme deficiency or poorly absorbed glucose-galactose.

Carvestad 6.25 contains saccharose. This medication should not be used for patients with rare genetic problems that are fructose intolerance, glucose-galactose malabsorption or the deficiency of sucrase-isomaltase enzymes. Carvedilol must be used in patients with congestive heart failure treatment with digitalis, diuretics, or enzyme inhibitors that transferred angiotensin because the atrial transmission may be slowed.

Must be used carefully in people with diabetes without or difficult to control, because beta receptor blockers can cover symptoms of blood glucose.

Must stop treatment when there is signs of liver damage.

Must be cautious in peripheral blood vessel patients, patients are suffering from anesthesia, people with hyperthyroidism.

If the patient does not tolerate other anti -hypertension drugs, caution can be used with very small doses of carvedilol for people with bronchospasm.

Avoid stopping the drug suddenly, to stop the drug for 1-2 weeks. The risk of arrhythmia must be considered, if used carvedilol simultaneously with anesthetic inhalation. The risk must be considered if combined with carvedilol with anti -arrhythmia group I.

Not yet determined the safety and effectiveness of Carvedilol in children.

The ability to drive and operate machinery

as well as other drugs that change blood pressure, patients taking carvedilol should be cautious should not drive or operate machinery if you feel dizzy or have related symptoms. Especially when starting or changing the way of treatment and during simultaneous use with alcohol.

Pregnancy

Carvedilol has caused clinical damage in the fetus. Only use this drug during pregnancy if the expected benefits are higher than the risk that may occur and as usual, not used in the last three months of pregnancy or near labor.

Unwanted effects for fetuses such as slow heartbeat, hypotension, respiratory inhibition, blood glucose and body temperature reduction in infants can be used by pregnancy.

The period of breastfeeding

The drug can be excreted into breast milk. There is no risk of unwanted effect in breastfeeding.

Drug interaction

Rifampicin may reduce the plasma of carvedilol plasma by 70%. The effect of other beta blockers decreases when combined with aluminum salts, barbiturat, calcium salts, cholestyramin, colestipol, non -selective α1 receptor blockers, penicillin (ampicillin), salicylate, and sulfinyrazon due to reduced bioavailability and plasma concentration.

Carvedilol can increase the effects of anti -diabetic drugs, calcium channel blockers, digoxin.

Carvedilol's interaction with clonidin can lead to an increase in blood pressure and reduce heart rate.

cimetidine increases the effects and bioavailability of carvedilol.

Other drugs that are capable of increasing the concentration and effects of carvedilol include quinidin, fluoxetin, paroxetin, and propafenon because these drugs inhibit CYP2D6.

Carvedilol increases the concentration of digoxin about 20% when taken at the same time.

Cyclosporin: There is a moderate increase in the average bottom concentration of cyclosporin after starting treatment with carvedilol in 21 kidney transplant patients with chronic blood vessels. In about 30% of patients, the dosage of cyclosporin must be reduced to maintain cyclosporin levels during the therapeutic dose, while the remaining patients do not need to adjust the dose.

On average, Cyclosporin dose decreased by about 20% in these patients. Because there are many changes between individuals in adjusting the dose, it is recommended to closely monitor cyclosporin concentration after starting carvedilol treatment and appropriate cyclosporin dose adjustment.

Storage

Store in closed packaging, dry place. The temperature does not exceed 30 ° C.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.